Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy
Helsinki, Finland, 19 April 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary ‘PeptiBAC’ technology from the University of Helsinki, Finland.
PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases, specifically tuberculosis (TB, caused by Mycobacterium tuberculosis (MTB)), as well therapeutic potential in canc